Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial

Patricia R. M. Rocco, Pedro L. Silva, Fernanda F. Cruz, Marco Antonio C. M. Junior, Paulo F. G. M. M. Tierno, Marcos A. Moura, Luís Frederico G. De Oliveira, Cristiano C. Lima, Ezequiel A. Dos Santos, Walter F. Junior, Ana Paula S. M. Fernandes, Kleber G. Franchini, Erick Magri, Nara F. de Moraes, José Mário J. Gonçalves, Melanie N. Carbonieri, Ivonise S. Dos Santos, Natália F. Paes, Paula V. M. Maciel, Raissa P. Rocha, Alex F. de Carvalho, Pedro Augusto Alves, José Luiz P. Modena, Artur T. Cordeiro, Daniela B. B. Trivella, Rafael E. Marques, Ronir R. Luiz, Paolo Pelosi, Jose Roberto Lapa e Silva on behalf of the SARITA-2 investigators
doi: https://doi.org/10.1101/2020.10.21.20217208
Patricia R. M. Rocco
1Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: prmrocco@biof.ufrj.br
Pedro L. Silva
1Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fernanda F. Cruz
1Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Antonio C. M. Junior
2Hospital Municipal de Emergências Albert Sabin, São Caetano, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paulo F. G. M. M. Tierno
3Hospital Municipal de Barueri Dr Francisco Moran, Barueri, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcos A. Moura
4Hospital e Maternidade Therezinha de Jesus, Juiz de Fora, Minas Gerais, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luís Frederico G. De Oliveira
5Hospital Santa Casa de Misericórdia de Sorocaba, Sorocaba, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristiano C. Lima
6Secretaria de Estado de Saúde do Distrito Federal, Brasília, Distrito Federal, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ezequiel A. Dos Santos
7Secretaria Municipal de Saúde de Bauru, Bauru, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Walter F. Junior
8Secretaria Municipal de Saúde de Guarulhos, Guarulhos, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Paula S. M. Fernandes
9Centro de Tecnologia de Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kleber G. Franchini
10Brazilian National Biosciences Laboratory (LNBio) and Brazilian Center for Energy and Materials Research (CNPEM), Campinas, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erick Magri
2Hospital Municipal de Emergências Albert Sabin, São Caetano, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nara F. de Moraes
3Hospital Municipal de Barueri Dr Francisco Moran, Barueri, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
José Mário J. Gonçalves
4Hospital e Maternidade Therezinha de Jesus, Juiz de Fora, Minas Gerais, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melanie N. Carbonieri
5Hospital Santa Casa de Misericórdia de Sorocaba, Sorocaba, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ivonise S. Dos Santos
6Secretaria de Estado de Saúde do Distrito Federal, Brasília, Distrito Federal, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natália F. Paes
7Secretaria Municipal de Saúde de Bauru, Bauru, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paula V. M. Maciel
8Secretaria Municipal de Saúde de Guarulhos, Guarulhos, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raissa P. Rocha
9Centro de Tecnologia de Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex F. de Carvalho
9Centro de Tecnologia de Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pedro Augusto Alves
11Instituto René Rachou – Fiocruz, Belo Horizonte, Minas Gerais, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
José Luiz P. Modena
12State University of Campinas, Campinas, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Artur T. Cordeiro
10Brazilian National Biosciences Laboratory (LNBio) and Brazilian Center for Energy and Materials Research (CNPEM), Campinas, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela B. B. Trivella
10Brazilian National Biosciences Laboratory (LNBio) and Brazilian Center for Energy and Materials Research (CNPEM), Campinas, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rafael E. Marques
10Brazilian National Biosciences Laboratory (LNBio) and Brazilian Center for Energy and Materials Research (CNPEM), Campinas, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronir R. Luiz
1Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paolo Pelosi
13Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Genoa, Italy
14San Martino Policlinico Hospital, IRCCS for Oncology and Neurosciences, Genoa, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jose Roberto Lapa e Silva
1Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

The antiparasitic drug nitazoxanide is widely available and exerts broad-spectrum antiviral activity in vitro. However, there is no evidence of its impact on SARS-CoV-2 infection.

In a multicenter, randomized, double-blind, placebo-controlled trial, adult patients who presented up to 3 days after onset of Covid-19 symptoms (dry cough, fever, and/or fatigue) were enrolled. After confirmation of SARS-CoV2 infection by RT-PCR on nasopharyngeal swab, patients were randomized 1:1 to receive either nitazoxanide (500 mg) or placebo, TID, for 5 days. The primary outcome was complete resolution of symptoms. Secondary outcomes were viral load, general laboratory tests, serum biomarkers of inflammation, and hospitalization rate. Adverse events were also assessed.

From June 8 to August 20, 2020, 1,575 patients were screened. Of these, 392 (198 placebo, 194 nitazoxanide) were analyzed. Median time from symptom onset to first dose of study drug was 5 (4-5) days. At the 5-day study visit, symptom resolution did not differ between the nitazoxanide and placebo arms. However, at the 1-week follow-up, 78% in the nitazoxanide arm and 57% in the placebo arm reported complete resolution of symptoms (p=0.048). Swabs collected were negative for SARS-CoV-2 in 29.9% of patients in the nitazoxanide arm versus 18.2% in the placebo arm (p=0.009). Viral load was also reduced after nitazoxanide compared to placebo (p=0.006). No serious adverse events were observed.

In patients with mild Covid-19, symptom resolution did not differ between the nitazoxanide and placebo groups after 5 days of therapy. However, early nitazoxanide therapy was safe and reduced viral load significantly.

Take home message This was the first study to evaluate the effect of early nitazoxanide therapy in mild Covid-19. Nitazoxanide did not accelerate symptom resolution after 5 days of therapy; however, reduced viral load significantly with no serious adverse events.

Competing Interest Statement

Dr. Rocco reports personal fees from SANOFI as a DSMB member. The other authors declare no competing interests.

Clinical Trial

NCT04552483

Funding Statement

Supported by the Brazilian Council for Scientific and Technological Development (CNPq), Brazilian Ministry of Science, Technology, and Innovation for Virus Network; Brasilia, Brazil, number: 403485/2020-7 and Funding Authority for Studies and Projects, Brasilia, Brazil, number: 01.20.0003.00.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The IRB/oversight body was the Brazilian National Committee of Ethics in Research (CONEP), and the approval number is CAAE: 32258920.0.1001.5257. The study was further approved by local committees of ethics in research for the seven health units. The investigators have followed all appropriate research reporting guidelines. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The investigators plan on turning all individual participant data (IPD) available after the publication of the manuscript, with cautious of not sharing confidential data.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted October 23, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial
Patricia R. M. Rocco, Pedro L. Silva, Fernanda F. Cruz, Marco Antonio C. M. Junior, Paulo F. G. M. M. Tierno, Marcos A. Moura, Luís Frederico G. De Oliveira, Cristiano C. Lima, Ezequiel A. Dos Santos, Walter F. Junior, Ana Paula S. M. Fernandes, Kleber G. Franchini, Erick Magri, Nara F. de Moraes, José Mário J. Gonçalves, Melanie N. Carbonieri, Ivonise S. Dos Santos, Natália F. Paes, Paula V. M. Maciel, Raissa P. Rocha, Alex F. de Carvalho, Pedro Augusto Alves, José Luiz P. Modena, Artur T. Cordeiro, Daniela B. B. Trivella, Rafael E. Marques, Ronir R. Luiz, Paolo Pelosi, Jose Roberto Lapa e Silva
medRxiv 2020.10.21.20217208; doi: https://doi.org/10.1101/2020.10.21.20217208
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial
Patricia R. M. Rocco, Pedro L. Silva, Fernanda F. Cruz, Marco Antonio C. M. Junior, Paulo F. G. M. M. Tierno, Marcos A. Moura, Luís Frederico G. De Oliveira, Cristiano C. Lima, Ezequiel A. Dos Santos, Walter F. Junior, Ana Paula S. M. Fernandes, Kleber G. Franchini, Erick Magri, Nara F. de Moraes, José Mário J. Gonçalves, Melanie N. Carbonieri, Ivonise S. Dos Santos, Natália F. Paes, Paula V. M. Maciel, Raissa P. Rocha, Alex F. de Carvalho, Pedro Augusto Alves, José Luiz P. Modena, Artur T. Cordeiro, Daniela B. B. Trivella, Rafael E. Marques, Ronir R. Luiz, Paolo Pelosi, Jose Roberto Lapa e Silva
medRxiv 2020.10.21.20217208; doi: https://doi.org/10.1101/2020.10.21.20217208

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (230)
  • Allergy and Immunology (507)
  • Anesthesia (111)
  • Cardiovascular Medicine (1264)
  • Dentistry and Oral Medicine (207)
  • Dermatology (148)
  • Emergency Medicine (283)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (538)
  • Epidemiology (10056)
  • Forensic Medicine (5)
  • Gastroenterology (502)
  • Genetic and Genomic Medicine (2486)
  • Geriatric Medicine (240)
  • Health Economics (482)
  • Health Informatics (1653)
  • Health Policy (757)
  • Health Systems and Quality Improvement (638)
  • Hematology (250)
  • HIV/AIDS (538)
  • Infectious Diseases (except HIV/AIDS) (11896)
  • Intensive Care and Critical Care Medicine (627)
  • Medical Education (255)
  • Medical Ethics (75)
  • Nephrology (269)
  • Neurology (2304)
  • Nursing (140)
  • Nutrition (354)
  • Obstetrics and Gynecology (458)
  • Occupational and Environmental Health (537)
  • Oncology (1259)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (326)
  • Pediatrics (737)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2295)
  • Public and Global Health (4850)
  • Radiology and Imaging (846)
  • Rehabilitation Medicine and Physical Therapy (493)
  • Respiratory Medicine (657)
  • Rheumatology (289)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (228)
  • Surgery (273)
  • Toxicology (44)
  • Transplantation (131)
  • Urology (100)